Myriad Genetics detailed a strategic product roadmap at JP Morgan, saying it will launch five tissue‑informed minimal residual disease (MRD) tests over the next two years targeting breast, renal, colorectal, endometrial and ovarian cancers. The company will begin limited breast MRD access in Q1 2026 and pursue MolDx coverage and staged commercial rollouts through 2027. Myriad also flagged an AI‑enabled Prolaris prostate cancer test and expanded hereditary and prenatal panels as growth drivers. The presentation outlined ongoing MRD clinical studies and reimbursement plans—indicating Myriad’s intent to build a diversified diagnostics portfolio centered on longitudinal cancer surveillance.